Psoriasis, a chronic skin disease with no known cure, causes a rash with red, scaly patches that itch, primarily on the knees, elbows, trunk, and scalp. It can be painful, disrupt sleep, and make it difficult to concentrate, thus affecting the overall quality of life.
Coriodermina: An Innovative Approach to Psoriasis Treatment
The Cuban Medical Services Trading Company, S.A. offers a revolutionary therapeutic program for psoriasis using a medication derived from human placenta, known as Coriodermina. This treatment has shown remarkable efficacy, with a 78% success rate in treated patients, and no significant adverse reactions. Its safety allows it to be used in children, adults, including the elderly, pregnant women, and women during their menstrual periods.
The medication is presented as a water-soluble gel and is applied topically without rubbing over the psoriatic lesions, making it a simple and safe option for patients. It has proven effective in relieving the symptoms of psoriasis, providing individuals with a significant improvement in their quality of life.
The treatment process begins with a three-day stay at the International Clinical Service of the Placental Histotherapy Center in Cuba. During this period, patients undergo a comprehensive medical evaluation to confirm the diagnosis and determine the precise amount of medication to be used in their home country for effective results.
It is important to note that patients must discontinue any other medical treatment 45 days before their visit to Cuba. If skin biopsy results are not available, they can be performed during the medical evaluation.
How to Access the Treatment
To begin the treatment, interested individuals must contact the Coordination and Processing Center of the Cuban Medical Services Trading Company, S.A. via email at smc@smcsalud.cu. Once in contact, they will be provided with the complete medical program along with the associated costs.
In a world where psoriasis is a constant struggle for many, Coriodermina stands as a promising option, offering new hope and relief for those living with this chronic skin disease.
By: MSc. Dr. Patricia Alonso Galbán
Communication Specialist at CSMC, S.A.